ITGA2B and Macrothrombocytopenia: Although the two types of αIIbβ3 mutations downregulate RhoA through different molecular mechanisms, targeted modulation of the RhoA/ROCK pathway may represent a therapeutic strategy for ITGA2B/ITGB3‐related macrothrombocytopenia.